Search Results
Sep 09, 2026, 10:00 ET PostEra's Fertility programs acquired by EMD Serono, Inc.
injections to an all-oral regimen; a step-change in treatment for women undergoing IVF.EMD Serono has acquired PostEra's FSHR and LHCGR agonist programs. Following completion of the transaction, EMD Serono will assume sole responsibility for the continued development and potential commercialization
More news about: PostEra
Sep 09, 2026, 10:00 ET PostEra's Fertility programs acquired by EMD Serono, Inc.
injections to an all-oral regimen; a step-change in treatment for women undergoing IVF.EMD Serono has acquired PostEra's FSHR and LHCGR agonist programs. Following completion of the transaction, EMD Serono will assume sole responsibility for the continued development and potential commercialization
More news about: PostEra
Sep 09, 2026, 10:00 ET Die Fertilitätsprogramme von PostEra wurden von EMD Serono, Inc. übernommen
entscheidender Fortschritt bei der Behandlung von Frauen, die sich einer IVF unterziehen.EMD Serono hat die Programme von PostEra für FSHR- und LHCGR-Agonisten übernommen. Nach Abschluss der Transaktion wird EMD Serono die alleinige Verantwortung für die weitere Entwicklung sowie die mögliche Vermarktung
More news about: PostEra
Sep 09, 2026, 10:00 ET Los programas de fertilidad de PostEra, adquiridos por EMD Serono, Inc.
que supondría un avance cualitativo en el tratamiento para las mujeres sometidas a FIV.EMD Serono ha adquirido los programas de agonistas de FSHR y LHCGR de PostEra. Tras completarse la transacción, EMD Serono asumirá la responsabilidad exclusiva del desarrollo continuo y la posible comercialización
More news about: PostEra
Sep 09, 2026, 10:00 ET Les programmes de fertilité de PostEra ont été rachetés par EMD Serono, Inc.
avancée majeure dans la prise en charge des femmes suivant un traitement de la FIV.EMD Serono a racheté les programmes de PostEra portant sur les agonistes du FSHR et du LHCGR. Une fois la transaction finalisée, EMD Serono prendra complètement en charge la poursuite du développement et la commercialisation
More news about: PostEra
Sep 03, 2026, 10:31 ET Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight
the key osteosarcoma companies, including Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics, and others.
More news about: DelveInsight Business Research, LLP
Aug 26, 2026, 10:41 ET Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna
More news about: DelveInsight Business Research, LLP
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
key Checkpoint Inhibitor Refractory Cancer companies, including BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra
More news about: DelveInsight Business Research, LLP
Aug 18, 2026, 09:00 ET PM360 Announces 2026 Trailblazer Award Finalists
Self-Advocacy (Sumitomo Pharma America, Inc. and CMI Media Group)GOMEKLI Guides Ambassador Program (Snow Companies and SpringWorks Therapeutics/EMD Serono)Wegovy.com (Novo Nordisk and Inizio Evoke)DIRECT-TO-CONSUMER CAMPAIGNLILY AND KAYLEB (Biolumina,
More news about: PM360
Aug 10, 2026, 14:45 ET Society for Immunotherapy of Cancer Forward Fund Announces 2026 Fellowship Recipients, Awarding $150,000 to Support the Next Generation of Cancer Immunotherapy Researchers
2027-2028 NCI Immunotherapy Fellowship. The 2026 SITC Forward Fund fellowships are made possible through the generous support of EMD Serono, Merck and the Society for Immunotherapy of Cancer.To learn more about current and past SITC fellowship recipients, visit the
More news about: Society for Immunotherapy of Cancer (SITC)
Aug 07, 2026, 08:16 ET The U.S. Air Force Awards $8.22M to Intellisense Systems to Develop Next Generation Nuclear Flash Blindness Goggles
2026 /PRNewswire/ -- Intellisense Systems, Inc. has been awarded an $8,218,891 Cost Plus Fixed-Fee (CPFF) Engineering and Manufacturing Development (EMD) and Low-Rate Initial Production (LRIP) contract to develop Next Generation Nuclear Flash Blindness protection systems to protect aircrews from nuclear
More news about: Intellisense Systems, Inc.
Jul 23, 2026, 10:31 ET ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna
More news about: DelveInsight Business Research, LLP
Jul 14, 2026, 09:00 ET Inductive Bio Wins 3rd Consecutive AI Drug Discovery Benchmark
Inductive placed first in all three challenges, even against entrants from companies many times its size, including Merck (with NVIDIA), Novo Nordisk, EMD Serono, and more.Inductive's work on PXR is part of a broader drug safety focus for the company, which was selected to lead an up to $21M ARPA-H
More news about: Inductive Bio, Inc.
Jul 06, 2026, 14:50 ET The Inner Circle acknowledges Amy F Su, PMP as a Pinnacle Professional of The Year.
exploration and mission reliability.At Senior Aerospace SSP, she was instrumental in executing the Engineering and Manufacturing Development (EMD) phase of the Bleed Air Duct System and APU Exhaust Duct Assembly for the United States Air Force's T-7A (Red Hawk) Trainer Program in collaboration
More news about: The Inner Circle
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
13.4.10TEPMETKO (Tepotinib): EMD Serono (Merck KGaA)13.4.11
More news about: DelveInsight Business Research, LLP
Jun 30, 2026, 09:31 ET Lupus Ventures Appoints Investment Committee, Scientific Advisory Network, and Unique Patient Council to Inform Fund Strategy
Immunology, Eli Lilly and CompanyTimothy B. Niewold, MD, FACR, Hospital for Special SurgeryHarsukh Parmar, MD, former SVP, Immunology, EMD SeronoWilliam H. Robinson, MD, PhD, Stanford UniversityPeter Schafer, PhD, Chair, PROLIFIC Consortium, Pulmonary Fibrosis FoundationTeodora
More news about: Lupus Research Alliance
Jun 25, 2026, 06:10 ET Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's
More news about: Bio-Techne Corporation
Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
(sCR), 7 very good partial responses (VGPR), and 9 partial responses (PR). In this cohort, the ORR was 80% among 10 patients with extramedullary disease (EMD) and 77.8% among 9 patients previously treated with BCMA- and/or GPRC5D-directed therapies. Among patients who achieved complete response or better,
More news about: Innovent Biologics
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna
More news about: DelveInsight Business Research, LLP
Jun 09, 2026, 10:01 ET Electrolytic Manganese Dioxide (EMD) Market to Reach USD 1.45 Billion by 2032 Amid Battery Demand Growth | Valuates Reports
Manganese Dioxide (EMD) Market?Alkaline Battery Grade EMDZinc Manganese and Zinc-Carbon Battery Grade EMDLithium-ion Battery Grade EMDOther Grade EMDWhat are the major purity types in the Electrolytic Manganese Dioxide (EMD) Market?
More news about: Valuates Reports
May 20, 2026, 14:36 ET CureDuchenne Appoints Lidia Gardner, PhD, EMBA, as Vice President of Clinical and Medical Affairs to Advance Patient-Centered Care, Research, and Strategic Partnerships
Neurology & Immunology at EMD Serono, a business of Merck KGaA, Darmstadt, Germany. In that role, she led global medical strategy for neuroimmunology programs and collaborated across clinical development, regulatory, real-world evidence, and commercial teams. Prior to joining EMD Serono, she worked in Medical
More news about: CureDuchenne
May 19, 2026, 16:00 ET NIIMBL Announces 8 New Technology and Workforce Projects
ProjectsProject: Continuous and Automated Downstream Purification of AAVLead: Michigan Technological UniversityParticipants: Cytiva, EMD Millipore Corporation, Janssen, Landmark Bio, and PAK BioSolutionsProject: Leveraging Multidimensional Partner Data to Develop Predictive Digital
More news about: National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Apr 29, 2026, 16:04 ET Bramshill Investments' Portfolio Manager, Arif Joshi, featured on Bloomberg Intelligence FICC Focus
his 15 years at Lazard, he grew the EMD platform to $18bn of AUM, across both long-only and total return strategies. Arif served as a portfolio manager for both USD and local currency strategies and was also responsible for top-down macroeconomic views for the EMD platform. Prior to Lazard, Arif was
More news about: Bramshill Investments, LLC
Apr 22, 2026, 10:00 ET Lupus Advocates Take Action on Capitol Hill to Ensure Access to Care and Increase Research Funding
generous donors, and corporate partners whose support helped make the 2026 National Lupus Advocacy Summit possible: AstraZeneca, Biogen, Cabaletta Bio, EMD Serono, Genentech, GSK, Novartis, PhRMA, UCB, and Viatris.About the Lupus Foundation of AmericaThe Lupus Foundation of America is
More news about: Lupus Foundation of America, Inc.
Apr 09, 2026, 03:25 ET Aktia Bank Plc expands its distribution network in Europe through three new sales partnerships
Luxembourg: Oceanside Capital PartnersOceanside Capital Partners has represented Aktia's EMD strategies in the Netherlands since autumn 2025. We are now pleased to announce that coverage of both our EMD and Credit strategies is expanding to Belgium and Luxembourg."We are delighted to further
More news about: Aktia Bank